Development and Characterization of Liposomal Doxorubicin Hydrochloride with Palm Oil

Table 2

IC50 of Fa, Fb, and Caelyx^R after 48 hours of treatment.

Formulation	IC50 MCF7; (𝜇g/mL, 𝑛=3)	IC50 MDA-MBA 231; (𝜇g/mL, 𝑛=3)
Fa	376.45±9.20	726.40±7.58
Fb	387.22±6.93	755.73±6.81
Caelyx^R	483.84±7.78	972.91±9.87